Department of Sexually Transmitted Diseases Prevention and Control, Xi'an Centers for Disease Control and Prevention, Xi'an, China.
Department of Health Professions, School of Health Professions and Human Services, Hofstra University, Hempstead, New York.
J Med Virol. 2019 Jul;91(7):1263-1271. doi: 10.1002/jmv.25449. Epub 2019 Mar 27.
The number of men who have sex with men (MSM) living with human immunodeficiency virus (HIV) in China has increased rapidly and thus immediate highly active antiretroviral therapy (HAART) after diagnosis was implemented as a strategy to reduce the HIV transmission.
MSM who were diagnosed with HIV and received HAART between 2013 to 2015 in Xi'an were divided into three groups (>350, 200-350, and <200 cell/μL) according to their baseline CD4+ T cell count. The time of follow-up was calculated from the first date of receiving HAART to December 31, 2016. The CD4+ T cell count was detected with 1 week before or after HAART. The plasma viral loads were tested after 1, 2, and 3 years of treatment.
Of 1442 subjects who received HAART, 690 (47.9%) cases were in >350 cell/μL group, whereas 400 (27.7%) cases and 352 (24.4%) cases were in the 200-350 cell/μL group and <200 cell/μL group, respectively. After 1 year of treatment, the viral suppression rate in the <200 cell/μL group was 91.1%, which was significantly lower than the other two groups. The logistic regression results show that the >350 cell/μL group and 200-350 cell/μL group predicted higher viral suppression rates.
Baseline CD4+ T cell count more than 350 cell/μL can improve viral suppression among MSM living with HIV. Furthermore, to reduce the transmission risk, the treatment compliance of people living with HIV with high CD4+ T cell levels should be improved, and their diagnosis to the treatment time should be decreased.
中国男男性行为者(MSM)中感染人类免疫缺陷病毒(HIV)的人数迅速增加,因此实施了诊断后立即给予高效抗逆转录病毒治疗(HAART)的策略,以降低 HIV 传播。
将 2013 年至 2015 年在西安诊断为 HIV 并接受 HAART 的 MSM 根据基线 CD4+T 细胞计数分为三组(>350、200-350 和<200 个/μL)。随访时间从开始接受 HAART 之日起计算至 2016 年 12 月 31 日。在 HAART 前后 1 周内检测 CD4+T 细胞计数。在治疗 1、2 和 3 年后检测血浆病毒载量。
在接受 HAART 的 1442 名受试者中,690 例(47.9%)处于>350 个/μL 组,400 例(27.7%)和 352 例(24.4%)分别处于 200-350 个/μL 组和<200 个/μL 组。治疗 1 年后,<200 个/μL 组的病毒抑制率为 91.1%,明显低于其他两组。logistic 回归结果表明,>350 个/μL 组和 200-350 个/μL 组预测病毒抑制率更高。
基线 CD4+T 细胞计数>350 个/μL 可提高 HIV 感染者的病毒抑制率。此外,为了降低传播风险,应提高 CD4+T 细胞水平较高的 HIV 感染者的治疗依从性,并缩短其从诊断到治疗的时间。